Yim Jisook, Lee Yangsoon, Kim Myungsook, Seo Young Hee, Kim Wan Hee, Yong Dongeun, Jeong Seok Hoon, Lee Kyungwon, Chong Yunsop
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea.
Ann Lab Med. 2015 Jan;35(1):94-8. doi: 10.3343/alm.2015.35.1.94. Epub 2014 Dec 8.
Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea.
A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method.
Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The MIC50 and MIC90 of tigecycline were 2-4 µg/mL and 8-16 µg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole.
Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively.
需要定期监测临床上重要的厌氧菌（如脆弱拟杆菌属菌群）的耐药趋势。我们测定了2009年至2012年在韩国一家三级医院分离出的脆弱拟杆菌属菌群临床分离株的抗菌药敏情况。
在一家三级医院共收集了180株非重复的脆弱拟杆菌属菌群临床分离株。通过常规方法进行菌种鉴定：ATB 32A快速鉴定系统（法国生物梅里埃公司）和Vitek MS基质辅助激光解吸/电离飞行时间质谱仪（生物梅里埃公司）。采用美国临床和实验室标准协会（CLSI）琼脂稀释法测定抗菌药敏情况。
脆弱拟杆菌属菌群分离株对亚胺培南和美罗培南的耐药率为0%至6%。脆弱拟杆菌对哌拉西林-他唑巴坦的耐药率为2%，其他拟杆菌属菌种为0%，但多形拟杆菌分离株的耐药率为17%。多形拟杆菌和其他拟杆菌属菌种对哌拉西林（72%和69%）、头孢替坦（89%和58%）和克林霉素（83%和69%）的耐药率较高。其他拟杆菌属菌种对莫西沙星的耐药率为27%。替加环素的MIC50和MIC90分别为2至4μg/mL和8至16μg/mL。没有分离株对氯霉素或甲硝唑耐药。
亚胺培南、美罗培南、氯霉素和甲硝唑对脆弱拟杆菌属菌群分离株仍具活性。脆弱拟杆菌属菌群分离株对莫西沙星和替加环素的耐药率分别为2%至27%和8%至15%。
